Therapeutic intervention for Group C: standard-of-care Therapeutic intervention for Group R: standard-of-care and RE therapy
After eight weeks of therapy, the HOMA-β in Group R was statistically significantly higher than that in Group C, and the HOMA-IR in Group R was statistically significantly lower than in Group C. HOMA-β is an index of remaining endogenous insulin secretory capacity, and HOMA-IR is an index of insulin resistance.
From these, adding RE therapy to the standard-of-care was inferred to have the following effects: Reducing insulin resistance reduces the amount of insulin required for hypoglycemia. This alleviates the burden on pancreatic beta cells and increases their residual insulin secretion capacity.
